U.S. Biologics Contract Development Market (2025 - 2033) Size, Share, & Trends Analysis Report By Source (Mammalian, Microbial), By Product Service (Cell-line Development, Process Development), By Indication, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Source
                        1.2.2. Product Service
                        1.2.3. Indication
                        1.2.4. Estimates and forecasts timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market formulation & Validation
                    1.7. Model Details
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Source Outlook
                        2.2.2. Product Service Outlook
                        2.2.3. Indication Outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Biologics Contract Development Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook
                        3.1.2. Related/Ancillary Market Outlook
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                        3.2.2. Market Restraint Analysis
                    3.3. U.S. Biologics Contract Development Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                            3.3.1.1. Supplier Power
                            3.3.1.2. Buyer Power
                            3.3.1.3. Substitution Threat
                            3.3.1.4. Threat of New Entrant
                            3.3.1.5. Competitive Rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political Landscape
                            3.3.2.2. Technological Landscape
                            3.3.2.3. Economic Landscape
Chapter 4. U.S. Biologics Contract Development Market: Source Estimates & Trend Analysis
                    4.1. Source Segment Dashboard
                    4.2. U.S. Biologics Contract Development Market: Source Movement Analysis
                    4.3. U.S. Biologics Contract Development Market Size & Trend Analysis, by Source, 2021 - 2033 (USD Million)
                        4.3.1. Microbial
                            4.3.1.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                        4.3.2. Mammalian
                            4.3.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                        4.3.3. Others
                            4.3.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
Chapter 5. U.S. Biologics Contract Development Market: Product Service Estimates & Trend Analysis
                    5.1. Product Service Segment Dashboard
                    5.2. U.S. Biologics Contract Development Market: Product Service Movement Analysis
                    5.3. U.S. Biologics Contract Development Market Size & Trend Analysis, by Product Service, 2021 - 2033 (USD Million)
                        5.3.1. Cell Line Development
                            5.3.1.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                            5.3.1.2. Microbial
                                5.3.1.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                            5.3.1.3. Mammalian
                                5.3.1.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                            5.3.1.4. Others
                                5.3.1.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                        5.3.2. Process Development
                            5.3.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                            5.3.2.2. Upstream
                                5.3.2.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                                5.3.2.2.2. Microbial
                                    5.3.2.2.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                                5.3.2.2.3. Mammalian
                                    5.3.2.2.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                                5.3.2.2.4. Others
                                    5.3.2.2.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                            5.3.2.3. Downstream
                                5.3.2.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                                5.3.2.3.2. Bioanalytical Methods
                                    5.3.2.3.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                                    5.3.2.3.2.2. Impurity, isolation, & identification
                                        5.3.2.3.2.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                                    5.3.2.3.2.3. Physicochemical characterization
                                        5.3.2.3.2.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                                    5.3.2.3.2.4. Pharmaceutical analysis
                                        5.3.2.3.2.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                                    5.3.2.3.2.5. Others
                                        5.3.2.3.2.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                                5.3.2.3.3. Product
                                    5.3.2.3.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                                    5.3.2.3.3.2. MABs
                                        5.3.2.3.3.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                                    5.3.2.3.3.3. Recombinant proteins
                                        5.3.2.3.3.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                                    5.3.2.3.3.4. Others
                                        5.3.2.3.3.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
Chapter 6. U.S. Biologics Contract Development Market: Indication Estimates & Trend Analysis
                    6.1. Indication Segment Dashboard
                    6.2. U.S. Biologics Contract Development Market: Indication Movement Analysis
                    6.3. U.S. Biologics Contract Development Market Size & Trend Analysis, by Indication, 2021 - 2033 (USD Million)
                        6.3.1. Oncology
                            6.3.1.1. Market Estimates and Forecasts 2021 - 2033 (USD million)
                        6.3.2. Immunological Disorders
                            6.3.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                        6.3.3. Cardiovascular Disorders
                            6.3.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                        6.3.4. Hematological Disorders
                            6.3.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
                        6.3.5. Others
                            6.3.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
                    7.1. Recent Developments & Impact Analysis, By Key Market Participants
                    7.2. Company/Competition Categorization
                    7.3. Vendor Landscape
                        7.3.1. Key company heat map analysis, 2024
                    7.4. Company Profiles
                        7.4.1. WuXi Biologics.
                            7.4.1.1. Company overview
                            7.4.1.2. Financial performance
                            7.4.1.3. Product benchmarking
                            7.4.1.4. Strategic initiatives
                        7.4.2. Abzena
                            7.4.2.1. Company overview
                            7.4.2.2. Financial performance
                            7.4.2.3. Product benchmarking
                            7.4.2.4. Strategic initiatives
                        7.4.3. FUJIFILM Diosynth Biotechnologies.
                            7.4.3.1. Company overview
                            7.4.3.2. Financial performance
                            7.4.3.3. Product benchmarking
                            7.4.3.4. Strategic initiatives
                        7.4.4. KBI Biopharma
                            7.4.4.1. Company overview
                            7.4.4.2. Financial performance
                            7.4.4.3. Product benchmarking
                            7.4.4.4. Strategic initiatives
                        7.4.5. AGC Biologics.
                            7.4.5.1. Company overview
                            7.4.5.2. Financial performance
                            7.4.5.3. Product benchmarking
                            7.4.5.4. Strategic initiatives
                        7.4.6. Thermo Fisher Scientific Inc.
                            7.4.6.1. Company overview
                            7.4.6.2. Financial performance
                            7.4.6.3. Product benchmarking
                            7.4.6.4. Strategic initiatives
                        7.4.7. Curia Global, Inc.
                            7.4.7.1. Company overview
                            7.4.7.2. Financial performance
                            7.4.7.3. Product benchmarking
                            7.4.7.4. Strategic initiatives
                        7.4.8. GenScript
                            7.4.8.1. Company overview
                            7.4.8.2. Financial performance
                            7.4.8.3. Product benchmarking
                            7.4.8.4. Strategic initiatives
                        7.4.9. Bionova Scientific LLC
                            7.4.9.1. Company overview
                            7.4.9.2. Financial performance
                            7.4.9.3. Product benchmarking
                            7.4.9.4. Strategic initiatives
                        7.4.10. Boehringer Ingelheim International
                            7.4.10.1. Company overview
                            7.4.10.2. Financial performance
                            7.4.10.3. Product benchmarking
                            7.4.10.4. Strategic initiatives
                        7.4.11. STC Biologics
                            7.4.11.1. Company overview
                            7.4.11.2. Financial performance
                            7.4.11.3. Product benchmarking
                            7.4.11.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. biologics contract development market, by source, 2021 - 2033 (USD Million)
Table 3 U.S. biologics contract development market, by product service, 2021 - 2033 (USD Million)
Table 4 U.S. biologics contract development market, by indication, (USD Million) 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. biologics contract development market: market outlook
Fig. 10 U.S. biological contract development competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 U.S. biologics contract development market driver impact
Fig. 16 U.S. biologics contract development market restraint impact
Fig. 17 U.S. biologics contract development market strategic initiatives analysis
Fig. 18 U.S. biologics contract development market: source movement analysis
Fig. 19 U.S. biologics contract development market: source outlook and key takeaways
Fig. 20 Microbial market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 21 Mammalian market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 22 Others estimates and forecast, 2021 - 2033 (USD Million)
Fig. 23 U.S. biologics contract development market: product service movement analysis
Fig. 24 U.S. biologics contract development market: product service outlook and key takeaways
Fig. 25 Cell line development (2-17 years) market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 26 Microbial market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 27 Mammalian market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 28 Others market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 29 Process development market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 30 Upstream market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 31 Microbial market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 32 Mammalian market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 33 Others market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 34 Downstream market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 35 Analytical methods market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 36 Impurity, isolation, & identification market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 37 Physicochemical characterization market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 38 Pharmaceutical analysis market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 39 Others market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 40 Product market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 41 MABs market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 42 Recombinant proteins market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 43 Others market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 44 U.S. biologics contract development market: indication movement analysis
Fig. 45 U.S. biologics contract development market: indication outlook and key takeaways
Fig. 46 Hospital pharmacy estimates and forecast, 2021 - 2033 (USD Million)
Fig. 47 Oncology market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 48 Immunological Disorders market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 49 Cardiovascular Disorders market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 50 Hematological Disorders market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 51 Others market estimates and forecast, 2021 - 2033 (USD Million)